跳轉至內容
Merck
全部照片(1)

Key Documents

NCI-H69/LX4

96042329, human lung, Not specified

登入查看組織和合約定價


About This Item

分類程式碼代碼:
41106514

product name

NCI-H69/LX4, 96042329

生物源

human lung

增長模式

Aggregates in suspension

染色體組型

Not specified

形態學

Not specified

產品

Not specified

受體

Not specified

技術

cell culture | mammalian: suitable

相關疾病

cancer

運輸包裝

dry ice

儲存溫度

−196°C

細胞系來源

Human Caucasian small cell lung carcinoma, drug-resistant

細胞系描述

NCI-H69/LX4 has been established by exposure of the parent line, H69 (Sigma Catalogue number. 91091802) to doxorubicin, also known as adriamycin. The line hyperexpresses P-glycoprotein and demonstrates a multidrug resistant drug accumulation deficit. It is recommended to culture the cells without drug after resuscitation until the first passage.

應用

Analysis of acquired drug-resistance, study of small cell lung cancer

DNA分析

STR-PCR Data: Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 12
D16S539: 11
D5S818: 11,13
D7S820: 9
THO1: 8,9
TPOX: 10
vWA: 16,17

培養基

RPMI + 2mM Glutamine + 0.4μg/ml doxorubicine + 10% Foetal Bovine Serum (FBS).

例行更新培養

Split sub-confluent cultures (70-80%) by repeated pipetting of aggregates or scraping; 5% CO2; 37°C

其他說明

Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.

分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務